Skip Nav Destination
Issues
1 November 2013
-
Cover Image
Cover Image
miR-153 leads to increased invasiveness in colorectal cancer. Using mouse tumor xenografts, it was found that colorectal tumors with inhibition of miR-153 show a clean edge of tumor spheroid and fewer invasive fronts into the surrounding stroma (magnification, ×400) in contrast to controls with a more locally invasive tumor phenotype. For details, see article by Zhang and colleagues on page 6435. - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Breaking Advances
Reviews
Meeting Report
Priority Report
Integrated Systems and Technologies
Microenvironment and Immunology
Substance P Autocrine Signaling Contributes to Persistent HER2 Activation That Drives Malignant Progression and Drug Resistance in Breast Cancer
Susana Garcia-Recio; Gemma Fuster; Patricia Fernandez-Nogueira; Eva M. Pastor-Arroyo; So Yeon Park; Cristina Mayordomo; Elisabet Ametller; Mario Mancino; Xavier Gonzalez-Farre; Hege G. Russnes; Pablo Engel; Domiziana Costamagna; Pedro L. Fernandez; Pedro Gascón; Vanessa Almendro
Molecular and Cellular Pathobiology
miR-153 Supports Colorectal Cancer Progression via Pleiotropic Effects That Enhance Invasion and Chemotherapeutic Resistance
Lei Zhang; Karen Pickard; Veronika Jenei; Marc D. Bullock; Amanda Bruce; Richard Mitter; Gavin Kelly; Christos Paraskeva; John Strefford; John Primrose; Gareth J. Thomas; Graham Packham; Alex H. Mirnezami
Therapeutics, Targets, and Chemical Biology
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Bohua Li; Yanchun Meng; Lei Zheng; Xunmin Zhang; Qing Tong; Wenlong Tan; Shi Hu; Hui Li; Yang Chen; Jinjing Song; Ge Zhang; Lei Zhao; Dapeng Zhang; Sheng Hou; Weizhu Qian; Yajun Guo
Author Choice
A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance
Bingsen Zhou; Leila Su; Shuya Hu; Weidong Hu; M.L. Richard Yip; Jun Wu; Shikha Gaur; D. Lynne Smith; Yate-Ching Yuan; Timothy W. Synold; David Horne; Yun Yen
Tumor and Stem Cell Biology
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Xiaoping Wang; Hitomi Saso; Takayuki Iwamoto; Weiya Xia; Yun Gong; Lajos Pusztai; Wendy A. Woodward; James M. Reuben; Steven L. Warner; David J. Bearss; Gabriel N. Hortobagyi; Mien-Chie Hung; Naoto T. Ueno
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds